Zevra Therapeutics Inc（ZVRA）财务数据ZVRAZevra Therapeutics Inc

Evaluating the bottom line, Zevra Therapeutics, Inc. maintains a gross margin of 95.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.30%, while the net margin is 22.07%. These profitability ratios, combined with a Return on Equity (ROE) of 34.19%, provide a clear picture of how effectively ZVRA converts its operational activities into shareholder value.

In the context of the broader market, ZVRA competes directly with industry leaders such as PHAR and IRWD. With a market capitalization of $609.87M, it holds a significant position in the sector. When comparing efficiency, ZVRA's gross margin of 95.36% stands against PHAR's N/A and IRWD's 100.00%. Such benchmarking helps identify whether Zevra Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Zevra has shown significant revenue growth, with Q2 2026 net revenue at $39.7 million, a 53% increase year-over-year. The gross margin for Q2 2026 was 95.36%, indicating strong profitability potential. However, the company has a history of net losses, with a net income of $8.39 million in Q2 2026, following a loss of $30.7 million in Q4 2024.